PHVS Latest Press Releases

-- October 8, 2026 --

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet Globe Newswire 6:35 PM

-- October 5, 2026 --

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy Globe Newswire 6:50 AM

-- September 8, 2026 --

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks Globe Newswire 6:50 AM

-- September 3, 2026 --

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 Globe Newswire 6:50 AM

-- August 12, 2026 --

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 6:50 AM

-- August 6, 2026 --

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology Globe Newswire 6:50 AM

-- July 22, 2026 --

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema Globe Newswire 6:50 AM

-- July 6, 2026 --

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks Globe Newswire 6:50 AM

-- June 15, 2026 --

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Globe Newswire 6:50 AM

-- June 11, 2026 --

Pharvaris Announces Annual General Meeting of Shareholders Globe Newswire 6:50 AM

-- May 29, 2026 --

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 Globe Newswire 6:50 AM

Market Data Delayed 15 Minutes